摘要
目的观察重组人血管内皮抑制素（恩度）联合化、放疗治疗及维持治疗多种恶性实体瘤的疗效和安全性。方法 22例恶性实体肿瘤患者接受恩度静脉滴注联合多种常规化、放疗方案进行综合治疗。按照RECIST标准评价恩度用药2~4周期及多周期后的客观疗效;按照NCI CTC 3.0版的分级标准评价恩度治疗1周期及长期维持治疗药物毒性。结果经随访1~51个月,对使用恩度2周期的21例可评价病例中,CR 1例、PR 6例S、D 10例、PD 4例,总有效率为33.3%（初治vs复治：50%vs 31%）,临床受益率为80.9%（初治vs复治：100%vs 87%）;对使用恩度4周期的10例可评价病例中,PR 3例、SD 6例、PD 1例,有效率为40%,临床受益率为90%;对使用恩度维持治疗分别为8、14周期的2例患者评价,生活质量明显提高,病情分别稳定27、45个月。未观察到患者出现严重毒副反应。结论恩度联合化、放疗治疗多种恶性实体肿瘤近期疗效好,长期维持治疗病情稳定,初治效果优于复治效果,毒副反应可以耐受。提示恩度在肿瘤患者早期、维持治疗中值得推广应用。
Objective To evaluate the efficacy and safety of recombinant human endostatin（endostar） combined with standard radio-chemotherapy for various advanced solid tumors.Methods Twenty-two malignant solid tumor patients were administered routine radio-chemotherapy combined with endostar via intravenous drip infusion.The effectiveness of the combined therapy was evaluated after 2-4 treatment cycles and multi-cycles according to RECIST criteria.The toxicity of the endostar treatment was evaluated according to criterion of NCI CTC version 3.0 at the end of the first treatment cycle and cycles followed on.Results Twenty-one patients,who received endostar treatment for 2 cycles,were followed up for a period ranging from 1 to 51 months. Among the appraisable patients,one made a complete recovery（CR）,6 partial recovery（PR）,10 had stable disease（SD）,and 4 progressive disease（PD） with an overall efficacy rate of 33.3%（First treatment vs Second treatment： 50% vs 31%） and a clinical benefit rate of 80.9%（First treatment vs Second treatment： 100% vs 87%）.Ten appraisable patients received the combined treatment for 4 cycles. Among them,3 had PR,6 SD and 1 PD with an overall efficacy rate of 40% and a clinical benefit rate of 90%.Two patients received endostar for 8 and 14 cycles,respectively and were improved of life quality and remained stable for 27 and 45 months.No serious adverse events were observed.Conclusion Combined treatment of endostar with standard radio-chemotherapy has good recent clinical efficacy for patients with malignant solid tumors and maintenance therapy can stabilize the disease with a tolerable adverse event;the first treatment is better in the effect than the secondary treatment,thus suggesting endostar is worthy of wider application in early and maintenance treatment.
出处
《实用临床医药杂志》
CAS
2012年第7期21-23,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(41220008)
关键词
重组人血管内皮抑制素
实体肿瘤
维持治疗
疗效
安全性
recombinant human endostatin
solid tumors
maintenance therapy
therapeutic efficacy
therapeutic safety
